title: Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors.
abstract: Over the years, pharmacological intervention to prevent undesired intravascular coagulation and the associated detrimental effects has been a clinical challenge. The first generation of anticoagulant agents, warfarin and unfractionated heparin (UFH), involve indirect mechanisms of inhibiting the coagulation cascade. Fractionated, or low-molecular weight, heparins (LMWHs) are more selective for coagulation Factor Xa (FXa) over thrombin (FIIa). LMWHs also utilise an indirect mechanism of inhibition and have improved pharmacokinetic, pharmacodynamic and therapeutic profiles over UFH. The success of LMWHs, along with the pivotal location of FXa in the coagulation cascade, has prompted interest in the discovery and development of selective FXa inhibitors. There are two general classes of FXa inhibitors in development, of which SR90107A/ORG31540, an antithrombin-III-dependent pentasaccharide and DX-9065a, a small molecule direct FXa inhibitor, have published clinical data. SR90107A/ORG31540 and DX-9065a offer safe, predictable pharmacokinetic and pharmacodynamic profiles when administered subcutaneously and intravenously, respectively, to healthy volunteers and appear to be progressing through clinical development. The purpose of this review is to compile and summarise the published Phase I and II clinical data for SR90107A/ORG31540 and DX-9065a.
authors.affiliation: Information Research & Analysis, Department of Knowledge Management Services, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. Anthony.Porcari@wl.com.
authors.forename: A R
authors.initials: AR
authors.lastname: Porcari
authors.forename: L
authors.initials: L
authors.lastname: Chi
authors.forename: R
authors.initials: R
authors.lastname: Leadley
mesh_terms: D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D019774:Blood Coagulation Factor Inhibitors / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D065427:Factor Xa Inhibitors; D011134:Polysaccharides